Analysts think ABBV stock price could increase by 15%
Jun 03, 2025, 11:25 AM
-1.74%
What does ABBV do
AbbVie is a North Chicago-based biopharmaceutical company that develops and sells medicines across various therapeutic areas, employing 50,000 staff since its IPO in January 2013. Key products include Humira, Botox, and NX-13 for ulcerative colitis.
28 analysts think ABBV stock price will increase by 14.57%. The current median analyst target is $214.20 compared to a current stock price of $186.96. The lowest analysts target is $171.70 and the highest analyst target is $263.55.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
